Trial Profile
An Open-Label Randomized Study of Subcutaneous and Intravenous Velcade in Subjects With Previously Treated Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Johnson & Johnson; Millennium
- 15 Mar 2012 Additional location (England) added as reported by European Clinical Trials Database.
- 15 Mar 2012 Actual end date changed from Sep 2010 to Jan 2011 as reported by European Clinical Trials Database.
- 15 Mar 2012 This trial is recruiting in France as reported by European Clinical Trials Database.